Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | ADK | P55263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381869 | 0.85 | ADORA2A (0.36) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5813820 | 0.76 | GRIN2B (0.36) | ADORA2A | |
| SCHEMBL6887365 | 0.72 | TP53 (0.35) | TP53SMN1; SMN2HSD17B10 | |
| SCHEMBL17364300 | 0.71 | ADORA2A (0.38) | ADORA2ASMN1; SMN2ADORA1 | |
| SCHEMBL6880481 | 0.71 | SMN1; SMN2 (0.34) | TP53SMN1; SMN2HSD17B10ADK | |
| Ribose (Furanose) SCHEMBL5179410 | 0.65 | TP53 (0.61) | TP53SMN1; SMN2HSD17B10 | |
| SCHEMBL6378951 | 0.65 | MAPT (0.43) | SMN1; SMN2HSD17B10 | |
| SCHEMBL6381734 | 0.65 | KDM4E (0.39) | ADORA2ASMN1; SMN2 | |
| SCHEMBL4426228 | 0.64 | ADORA2A (0.72) | ADORA2ATP53SMN1; SMN2ADORA3ADORA2B | |
| SCHEMBL13598771 | 0.64 | ADORA2A (0.72) | ADORA2ATP53SMN1; SMN2ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | ADORA2A 174/4885TP53 1069/4885SMN1; SMN2 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.